...
首页> 外文期刊>Biotechnology Progress >Recombinase-Mediated Cassette Exchange (RMCE) for Monoclonal Antibody Expression in the Commercially Relevant CHOK1SV Cell Line
【24h】

Recombinase-Mediated Cassette Exchange (RMCE) for Monoclonal Antibody Expression in the Commercially Relevant CHOK1SV Cell Line

机译:重组酶介导的盒式交换(RMCE),用于在与商业相关的CHOK1SV细胞系中进行单克隆抗体表达

获取原文
获取原文并翻译 | 示例

摘要

To meet product quality and cost parameters for therapeutic monoclonal antibody (mAb) production, cell lines are required to have excellent growth, stability, and productivity characteristics. In particular, cell line generation stability is critical to the success of a program, especially where high cell line generation numbers are required for large in-market supply. However, a typical process for developing such cell lines is laborious, lengthy, and costly. In this study, we applied a FLP/FRT recombinase-mediated cassette exchange (RMCE) system to build a site-specific integration (SSI) system for mAb expression in the commercially relevant CHOK1SV cell line. Using a vector with a FRT-flanked mAb expression cassette, we generated a clonal cell line with good productivity, long-term production stability, and low mAb gene-copy number indicating the vector was located in a hot-spot.' A SSI host cell line was made by removing the mAb genes from the hot-spot' by RMCE, creating a landing pad' containing two recombination cassettes that allow targeting of one or two copies of recombinant genes. Cell lines made from this host exhibited excellent growth and productivity profiles, and stability for at least 100 generations in the absence of selection agents. Importantly, while clones containing two copies had higher productivity than single copy clones, both were stable over many generations. Taken together, this study suggests the use of FLP-based RMCE to develop SSI host cells for mAb production in CHOK1SV offers significant savings in both resources and overall cell line development time, leading to a shortened time-to-clinic' for therapeutic mAbs. (C) 2015 American Institute of Chemical Engineers
机译:为了满足生产治疗性单克隆抗体(mAb)的产品质量和成本参数,要求细胞系具有出色的生长,稳定性和生产率特征。特别是,细胞系生成的稳定性对于程序的成功至关重要,尤其是在大量市场供应需要高细胞系生成数量的情况下。但是,开发这种细胞系的典型方法是费力的,冗长的和昂贵的。在这项研究中,我们应用了FLP / FRT重组酶介导的盒式交换(RMCE)系统来构建用于在商业上相关的CHOK1SV细胞系中进行mAb表达的位点特异性整合(SSI)系统。使用带有FRT侧翼mAb表达盒的载体,我们产生了具有良好生产率,长期生产稳定性和低mAb基因拷贝数的克隆细胞系,表明该载体位于热点。通过用RMCE从热点处去除mAb基因,从而创建一个SSI宿主细胞系,创建一个包含两个重组盒的着陆垫,该重组盒可靶向一或两个拷贝的重组基因。在没有选择剂的情况下,由该宿主制得的细胞系表现出优异的生长和生产力状况,并且至少100代具有稳定性。重要的是,尽管包含两个副本的克隆比单个副本的克隆具有更高的生产率,但两者在许多世代中都是稳定的。综上所述,这项研究表明使用基于FLP的RMCE来开发SOK宿主细胞以在CHOK1SV中生产mAb的SSI宿主细胞可显着节省资源和整个细胞系的开发时间,从而缩短了治疗性mAb的上市时间。 (C)2015美国化学工程师学会

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号